Sign in
Not yet recruitingPhase 4

Aciclovir Versus Placebo for HSV-2 Meningitis

Key facts

Who runs it
Jacob Bodilsen
Where
Denmark8 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 4
People taking part
150 people, planned
Starts
1 Jan 2027
Expected to end
31 Dec 2032
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Acyclovir 50 MG/ML
  • Placebo
Record updated
28 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Adults ≥18 years of age admitted on suspicion of viral meningitis defined as:; A clinical presentation consistent with viral meningitis (e.g. headache, nuchal rigidity, photophobia, or fever) AND; Cerebrospinal fluid (CSF) pleocytosis (>4 leukocytes x 106/L) AND; HSV-2 positive by PCR of the CSF; Glasgow Coma Scale score of 15 AND; Ability to absorb oral medications

Who cannot take part

  • Patients fulfilling any of the following criteria will be excluded:; Encephalitis as defined by the International Encephalitis Consortium if diagnosed during standard care (see Glossary)20; Transverse myelitis as defined by the Transverse Myelitis Consortium Working Group if diagnosed during standard care (see Glossary)21; Severe immuno-compromise defined as an ongoing need for biological- or chemotherapy (e.g. natalizumab), prednisolone >20 mg/day for ≥14 days, uncontrolled HIV/AIDS (see glossary), haematological malignancies, and organ transplant recipients14,18,22; Moderate to severe concomitant genital herpes requiring systemic aciclovir; Pregnancy (proven by positive urine or plasma human chorionic gonadotropin test in fertile women); Hepatic impairment (aspartate aminotransferase or alanine aminotransferase levels >5 times the upper limit of normal); Impaired renal function (estimated glomerular filtration rate <25 mL/min); Intolerance to (val)aciclovir; Probenecid treatment; Systemic antiviral therapy with an antiherpetic effect for >24 hours; Previous enrolment into this trial

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation

The 2 groups in the trial

  • Active armExisting treatment, for comparison

    Randomisation to 7 days of active treatment with IV aciclovir 10 mg/kg q8h and possibility for oral step-down therapy with valaciclovir 1g q8h, or placebo (IV q8h and/or oral q8h).

    Treatment: Acyclovir 50 MG/ML

  • PlaceboPlacebo, for comparison

    Randomisation to 7 days of IV and/or oral placebo.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Aciclovir for HSV-2 Meningitis: A Double-blind Randomised Controlled Trial (AMEN)
Record updated
28 October 2026